Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testosterone loss and estradiol administration modify memory in men.

Tomasz M Beer1, Lisa B Bland, Joseph R Bussiere

  • 1Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA. beert@ohsu.edu

The Journal of Urology
|January 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remotely delivered resistance training program in adult sarcoma survivors: a pilot study.

BMC cancer·2026
Same author

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

Journal of gynecologic oncology·2026
Same author

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.

Journal for immunotherapy of cancer·2026
Same author

Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38).

Journal for immunotherapy of cancer·2025
Same author

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

The oncologist·2025
Same author

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.

Journal for immunotherapy of cancer·2025

Androgen deprivation therapy impairs long-term memory in prostate cancer patients. Estradiol therapy may reverse these cognitive deficits, improving memory performance in older men.

Area of Science:

  • Neuroendocrinology
  • Cognitive Neuroscience

Background:

  • Sex steroid receptors are prevalent in brain regions crucial for memory.
  • The impact of androgen deprivation therapy (ADT) on cognition remains poorly understood.

Purpose of the Study:

  • To investigate the effects of ADT on long-term and working memory in prostate cancer patients.
  • To assess the potential of estradiol therapy to mitigate cognitive decline associated with ADT.

Main Methods:

  • Cognitive assessments (verbal recall, SOP, Trails tests) and mood state evaluations were conducted at baseline and 4 weeks.
  • 18 prostate cancer patients receiving transdermal estradiol were compared to two control groups: 18 patients on ADT and 17 healthy men.

Main Results:

  • Patients on ADT showed significantly worse verbal memory compared to healthy controls.

Related Experiment Videos

  • Processing speed was slower in ADT patients, but working memory did not differ.
  • Estradiol therapy led to improvements in verbal memory performance.

    • Conclusions:

    • Sex steroid loss significantly impacts specific cognitive functions in older men.
    • Estrogen therapy demonstrates potential to counteract the negative effects of ADT on memory.